Skip to content
Gyre Therapeutics
Primary Menu
About
Overview
Management Team
Board of Directors
Science
Overview
Hydronidone
MASH
Other Disease Areas
Publications
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Contact
Activity measurements of dalcinonacog alfa
Post navigation
Previous:
The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable in the Thrombin Generation Test in Hemophilia A
Next:
Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia
X
Previous
Next
